Long-Term Immunological Alertness and Response to COVID-19 Vaccination—Conditions for Prevention in Early Palliative Oncological Care Patients DOI Creative Commons

Peter Priester,

Miroslav Fajfr,

Veronika Molnárová

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(3), P. 299 - 299

Published: March 13, 2024

Aside from the general population, COVID-19 pandemic has also affected a group of patients in palliative oncology care. In this study, long-term immune responses against SARS-CoV-2 after vaccination were monitored cohort This non-randomized, prospective, and open-label pilot study recruited Palliative Oncology Program included 147 patients, which 80 females (54.4%) 67 males (45.6%). The overall evaluation current health status, anti-S IgG titer, neutralizing antibodies using virus neutralization test (VNT). Anti-S antibody analysis revealed high (H) levels 35.7% (n = 10) very (VH) 39.3% 11) second dose. Similarly, third dose, H was found 29.6% 32) VH 55.5% 60) patients. High consistent with VNT titers (>2560) 17.1% 12) or 82.9% 58) Patients two more doses showed at median 451 342 days vaccination, respectively. clinical trial, over longer period time. These did not show reduced immunological to vaccine challenge. We can assume that prevention through reduce risk complications death early

Language: Английский

Outcomes of COVID‐19 in patients with lymphomas participating in registered clinical trials: A real‐world study from China in the Omicron outbreak era DOI Creative Commons
Peng Sun, Hang Yang,

Baitian Zhao

et al.

Cancer Medicine, Journal Year: 2023, Volume and Issue: 12(23), P. 21148 - 21158

Published: Nov. 27, 2023

Abstract Background This real‐world study investigated the outcome of COVID‐19 in lymphoma patients participating registered clinical trials and explored potential risk factors with during first wave Omicron outbreak China. Methods One hundred ten diagnosed our center between December 1, 2022, January 31, 2023, were included. Results Four (3.6%) identified as severe 2 (1.8%) critical COVID‐19, respectively. The mortality rate observed was 2.73% for entire cohort, 33.3% severe/critical group, 18.8% hospitalized group. 90‐day OS 98.2% 66.7% 87.5% Advanced age (≥70 years), comorbidities, PI3K inhibitor‐containing regimen significantly associated severity COVID‐19. Patients indolent B‐cell non‐Hodgkin lymphomas less likely to be Conclusion reported similar features cohort that non‐hematological malignancy (HM) patients, while proportion relatively higher than non‐HM patients. Our findings provided valuable experience aid researchers managing ongoing pandemic variant.

Language: Английский

Citations

2
Long-Term Immunological Alertness and Response to COVID-19 Vaccination—Conditions for Prevention in Early Palliative Oncological Care Patients DOI Creative Commons

Peter Priester,

Miroslav Fajfr,

Veronika Molnárová

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(3), P. 299 - 299

Published: March 13, 2024

Aside from the general population, COVID-19 pandemic has also affected a group of patients in palliative oncology care. In this study, long-term immune responses against SARS-CoV-2 after vaccination were monitored cohort This non-randomized, prospective, and open-label pilot study recruited Palliative Oncology Program included 147 patients, which 80 females (54.4%) 67 males (45.6%). The overall evaluation current health status, anti-S IgG titer, neutralizing antibodies using virus neutralization test (VNT). Anti-S antibody analysis revealed high (H) levels 35.7% (n = 10) very (VH) 39.3% 11) second dose. Similarly, third dose, H was found 29.6% 32) VH 55.5% 60) patients. High consistent with VNT titers (>2560) 17.1% 12) or 82.9% 58) Patients two more doses showed at median 451 342 days vaccination, respectively. clinical trial, over longer period time. These did not show reduced immunological to vaccine challenge. We can assume that prevention through reduce risk complications death early

Language: Английский

Citations

0